Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5

Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5

ABSTRACT: Objectives: Bebtelovimab is an anti-SARS-CoV-2 monoclonal antibody active against Omicron lineage variants authorized to treat high-risk outpatients with COVID-19. We sought to determine the real-world effectiveness of bebtelovimab during the Omicron phases BA.2/BA2.12.1/BA4/BA5. Methods:...

Full description

Bibliographic Details
Main Authors: Kyle C. Molina, Victoria Kennerley, Laurel E. Beaty, Tellen D. Bennett, Nichole E. Carlson, David A. Mayer, Jennifer L. Peers, Seth Russell, Matthew K. Wynia, Neil R. Aggarwal, Adit A. Ginde
Format: Article
Language:English
Published: Elsevier 2023-07-01
Series:International Journal of Infectious Diseases
Subjects:
Anti-SARS-COV-2 monoclonal antibody
COVID-19
Outpatient
Nonhospitalized
LY-CoV1404
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971223005258

Internet

http://www.sciencedirect.com/science/article/pii/S1201971223005258

Similar Items